LB-100 is primarily used in medical research, particularly in the study of cancer treatment. It functions as a potent inhibitor of protein phosphatase 2A (PP2A), an enzyme that plays a critical role in cell growth, division, and apoptosis. By inhibiting PP2A, LB-100 has shown potential in enhancing the effectiveness of chemotherapy and radiation therapy, making cancer cells more susceptible to these treatments. Research has explored its role in reducing tumor growth and improving outcomes in various cancer models, including breast, lung, brain, and colorectal cancers. LB-100 is currently under investigation in early clinical trials to evaluate its efficacy, often in combination with other therapies. Additionally, it is being studied for its potential to mitigate drug resistance in cancer cells, offering a promising avenue for developing more effective therapeutic strategies. Its application extends to preclinical studies, where it aids in understanding the mechanisms of cancer progression and treatment resistance.